Search - tctmd.com

Displaying 61 - 80 of 131

Sort: Relevancy | Date

A-fib Screening Yields Promising Results, But Uncertainty Remains: mSToPS and VITAL-AF

News Conference News

A-fib Screening Yields Promising Results, But Uncertainty Remains: mSToPS and VITAL-AF

November 19, 2020

Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib

News Conference News AHA 2020

Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib

November 14, 2020

Fish Oil, Vitamin D Don’t Prevent A-fib: VITAL Rhythm

News Conference News AHA 2020

Fish Oil, Vitamin D Don’t Prevent A-fib: VITAL Rhythm

November 13, 2020

MitraClip Viable in MI Patients With Acute MR, Including Patients in Shock: IREMMI

News Conference News TCT 2020

MitraClip Viable in MI Patients With Acute MR, Including Patients in Shock: IREMMI

Michael O'Riordan

October 17, 2020

Got Mail? Letter-Based Intervention Doesn’t Boost OAC Initiation for A-fib

News Conference News ESC 2020

Got Mail? Letter-Based Intervention Doesn’t Boost OAC Initiation for A-fib

September 03, 2020

First-line Ablation With Cryoballoon Gains Support From STOP AF First

News Conference News ESC 2020

First-line Ablation With Cryoballoon Gains Support From STOP AF First

September 02, 2020

Updated ESC A-fib Guidance Proposes New Path for Diagnosis, Classification, and Care

News Conference News ESC 2020

Updated ESC A-fib Guidance Proposes New Path for Diagnosis, Classification, and Care

August 30, 2020

News Conference News ESC 2020

Rhythm Control Cuts First CV Events in Early Atrial Fibrillation: EAST-AFNET 4

August 29, 2020

PINNACLE FLX: New-Generation Watchman Has High Closure Rates, Good Safety

News Conference News HRS 2020

PINNACLE FLX: New-Generation Watchman Has High Closure Rates, Good Safety

May 15, 2020

Aspirin Okay for Up to 30 Days

News Conference News ACC 2020

Aspirin Okay for Up to 30 Days in A-fib Patients After ACS or PCI: AUGUSTUS

April 03, 2020

A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI

News Conference News ACC 2020

A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI

March 29, 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

News Conference News ACC 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

March 25, 2020

Optimal Time to Start Anticoagulation After Stroke Remains Unclear

News Conference News ISC 2020

Optimal Time to Start Anticoagulation After Stroke Remains Unclear

February 27, 2020

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

News Conference News AHA 2019

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

November 20, 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

September 26, 2019

GARFIELD-AF Analysis Digs Into Impact of Bleeding in Newly Diagnosed A-fib

News Conference News ESC 2019

GARFIELD-AF Analysis Digs Into Impact of Bleeding in Newly Diagnosed A-fib

September 12, 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

September 11, 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

News Conference News ESC 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

September 10, 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

September 03, 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

September 02, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.